Aeolus Pharmaceuticals Announces Positive Results From Study of AEOL 10150

Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS:

), today announced preliminary results from a study of AEOL 10150 and Neupogen(R) conducted by Christie Orschell, PhD of Indiana University. The primary endpoint of the study was to determine drug-drug interactions between Neupogen(R) and AEOL 10150, as well as to monitor safety and tolerability of the two treatments given simultaneously. Results of the study confirmed that AEOL 10150 does not interfere with the positive effects of Neupogen(R) on the hematopoietic, or bone marrow, syndrome of Acute Radiation Syndrome (ARS), and the two products in combination were safe and well tolerated.